Recent Updates
Recently added Catalysts
ALT Positive Sentiment

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Thursday, February 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Altimmune, a biopharmaceutical company, will report its fourth quarter and full year 2025 financial results on March 5, 2026. The management will host a conference call to discuss these results and provide a business update. The call will be accessible via webcast, and a replay will be available for three months.
Price reaction · baseline $4.56 (2026-02-25 close) · hit pre-market · 1 other ALT headline(s) in the window, move may be shared
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune is progressing with its financial reporting schedule.
  • The company is focused on developing therapies for serious liver diseases.
  • The upcoming conference call will provide insights into business updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.
Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website athttps://ir.altimmune.com/investors.
Participants who would like to join the call may registerhereto receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visitwww.altimmune.com.

Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onX

Investor Contact:Lee RothBurns McClellanlroth@burnsmc.com

Media Contact:Real Chemistryaltimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

When will Altimmune report its financial results?

Altimmune will report its fourth quarter 2025 financial results on March 5, 2026.

How can I join the Altimmune conference call?

Participants can register online to receive dial-in numbers and a unique PIN for the call.

What is pemvidutide used for?

Pemvidutide is developed for treating serious liver diseases, including MASH and AUD.

Will there be a replay of the conference call?

Yes, a replay will be available on Altimmune's Investor Relations website for up to three months.

ShareAdd on Google
Tags: ALT Viatris Investor Conferences Healthcare Altimmune pemvidutide liver diseases financial results conference call
Last updated: Feb 26, 2026

Biotech snapshot

Cash runway
$519M liquidity · $8M/mo burn
~64 mo
Minimal dilution risk
Lead asset
ALT-801Phase 2
Obesity/Overweight →

Catalyst track record

+22%
best trade around ALT's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALT.

See every catalyst's timing & PoA →